Status
Conditions
Treatments
About
Multiple myeloma is the second most frequent hematologic malignancy, which incidence augmented between 1995 and 2018, with an annual mean variation of +0.6% to 1.1%. Although treatment improved in the last years, the patients' prognostic is associated with cytogenetic abnormalities.
Oncological supportive care provides patients with a global perspective, in addition to specific medical treatment adapted to pathology and patient profile. It contributes to the improvement of quality of life of patients, throughout their care pathway regarding physical, psychological and social aspects, according to their specific needs as well as their caregivers'.
The aim of this study is to evaluate the quality of life at 6 months after multiple myeloma diagnosis in outpatients receiving paramedical consultations in oncological supportive care from the diagnosis versus outpatients receiving paramedical consultations in oncological supportive care after 6 months after diagnosis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
20 participants in 2 patient groups
Loading...
Central trial contact
Doriane Richard, PhD; Amel Benchemam
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal